Adam's Take Adam Feuerstein STAT Plus: Reata’s ‘toss up’ drug approval decision is in the unpredictable hands of FDA’s Billy Dunn
Adam's Take Adam Feuerstein STAT Plus: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
Adam's Take Adam Feuerstein STAT Plus: An Anavex study spin job sullies an otherwise spectacular Alzheimer’s conference
Adam's Take Adam Feuerstein CytoDyn’s former CEO indicted for securities fraud. His misleading statements hurt patients even more than investors
Adam's Take Adam Feuerstein STAT Plus: Biotech’s ‘distracted boyfriend’ is $3 billion richer. His fellow investors are still waiting for their share
Adam's Take Adam Feuerstein STAT Plus: Mark Schoenebaum was the best biotech analyst ever. Better still, he was a great person
Adam's Take Adam Feuerstein STAT Plus: A dose of transparency by Cel-Sci does nothing to burnish its failed cancer immunotherapy
Adam's Take Adam Feuerstein STAT Plus: With Pfizer deal, Global Blood CEO sees opportunity to reach sickle cell patients globally
Adam's Take Adam Feuerstein STAT Plus: Not-so-happy midyear! Biotech CEOs, best and worst, and a hopeful sign of a turnaround
Adam's Take Adam Feuerstein STAT Plus: A cautionary tale: How one biotech stock trader lost a small fortune, but emerged wiser
Adam's Take Adam Feuerstein STAT Plus: Amylyx’s case for approval of its ALS drug isn’t ironclad. Here’s why I think it will still happen
Adam's Take Adam Feuerstein STAT Plus: It took years, but the failure of Northwest Bio’s brain cancer vaccine is now in the open
Adam's Take Adam Feuerstein STAT Plus: A company developing a human blood substitute attempts a comeback, but IPO plans look dicey
Adam's Take Adam Feuerstein STAT Plus: What Regeneron’s purchase of Checkmate Pharma says about the state of biotech
Adam's Take Adam Feuerstein STAT Plus: Cel-Sci’s CEO used private call to tip off select investors about cancer drug update
Adam's Take Adam Feuerstein STAT Plus: Troubles mount for Cassava Sciences, as patient enrollment lags for Alzheimer’s drug studies
Adam's Take Adam Feuerstein STAT Plus: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
Adam's Take Adam Feuerstein STAT Plus: An FDA ruling on Cassava’s Alzheimer’s drug leaves bulls and bears waiting for more
Adam's Take Adam Feuerstein STAT Plus: Be careful who you sue: CytoDyn knowingly submitted an incomplete drug application to FDA, new documents show
Adam's Take Adam Feuerstein STAT Plus: An FDA rejection derails Omeros, exposing the empty promises of its CEO
Adam's Take Adam Feuerstein STAT Plus: Northwest Bio marks ignominious anniversary of brain tumor study delay with silence
Adam's Take Adam Feuerstein STAT Plus: In new remarks, Cassava Sciences’ CEO shifts defense of embattled treatment for Alzheimer’s
Adam's Take Adam Feuerstein STAT Plus: Alzheimer’s scientists critique Cassava Sciences’ study results — overblown, inappropriate, uninterpretable
Adam's Take Adam Feuerstein STAT Plus: The failure of a cancer drug study leaves Cel-Sci on the brink of collapse
Adam's Take Adam Feuerstein STAT Plus: FDA issues major rebuke to CytoDyn over claims on Covid-19 drug
Adam's Take Adam Feuerstein STAT Plus: Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug
Adam's Take Adam Feuerstein STAT Plus: Fibrogen’s data manipulation scandal came with questions. There need to be answers
Adam's Take Adam Feuerstein STAT Plus: The long wait for Cel-Sci to finally admit its cancer drug doesn’t work
Adam's Take Adam Feuerstein STAT Plus: A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists
Adam's Take Adam Feuerstein STAT Plus: CytoDyn’s wild weekend of data-mining study results ends in failure for its Covid treatment
Adam's Take Adam Feuerstein STAT Plus: Who will Vertex buy? How much will it spend? Deal questions dominate its earnings call
Adam's Take Adam Feuerstein STAT Plus: Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list